In CML, BCR-ABL1 suppresses CXCR4-mediated signaling, thus altering the interactions between leukemic cells and the bone marrow stroma, which are defective. This evidence concerns the gene CXCR4 and chronic myelogenous leukemia, BCR-ABL1 positive.